Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02889796) enrolled a total of 1,759 people across several groups: 477 received filgotinib 200 mg, 480 received filgotinib 100 mg, 325 received adalimumab (an existing treatment used for comparison), and the remaining participants received a placebo (an inactive dummy treatment). The trial was primarily measuring how many people with rheumatoid arthritis showed at least a 20% improvement in joint tenderness, joint swelling, and several other disease markers after 12 weeks — a standard benchmark known as an "ACR20 response." It also tracked a range of other measurements, including physical function, quality of life, and changes visible on joint X-rays. The reported data shows that at the 12-week mark, 76.6% of participants in the filgotinib 200 mg group, 69.8% in the filgotinib 100 mg group, and 70.5% in the adalimumab group met the ACR20 response threshold, compared with 49.9% in the placebo group. For the secondary outcomes, the reported data shows changes in a physical disability score (HAQ-DI, where a lower number means less difficulty) — participants in the filgotinib 200 mg group had an average change of −0.69 points from their starting score, the 100 mg group −0.56, the adalimumab group −0.61, and the placebo group −0.42. On a disease activity score (DAS28-CRP, where a score below 2.6 is considered very low disease activity), 34.1% of the filgotinib 200 mg group reached that level at week 12, compared with 23.8% (100 mg), 23.7% (adalimumab), and 9.3% (placebo). X-ray scores measuring joint damage at 24 weeks showed average changes of 0.13 (filgotinib 200 mg), 0.17 (100 mg), 0.16 (adalimumab), and 0.37 (placebo) on a scale where smaller numbers indicate less change. A quality-of-life physical score (SF-36 PCS, where higher is better) improved by an average of 9.2 points in the filgotinib 200 mg group, 8.5 points in the 100 mg group, 8.4 points in the adalimumab group, and 5.8 points in the placebo group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 39592547) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Rheumatoid Arthritis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with rheumatoid arthritis (a condition where the immune system attacks the joints) based on recognised medical guidelines.
- Your rheumatoid arthritis is rated as functional class I, II, or III, meaning you have some ability to carry out daily activities (confirm with trial site).
- You have at least 6 swollen joints and at least 6 tender joints at both your initial screening appointment and at the start of the trial.
- You are currently taking a stable, unchanged dose of methotrexate (a common medication used to treat rheumatoid arthritis).
Who may not be able to join:
- You have previously taken any medication belonging to a group called JAK inhibitors (a type of drug used to treat inflammatory conditions) (confirm with trial site for specific examples).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Gilead Study Director, Gilead Sciences
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.